Whanin Pharm Cash Flow-to-Debt Ratio
Whanin Pharm cash flow-to-debt ratio. Whanin Pharm (016580) has a Cash Flow-to-Debt Ratio of 0.16x as of June 2026, meaning its operating cash flow of ₩9.26 Billion could theoretically repay 0% of its total liabilities (₩57.15 Billion) in one year. Check 016580 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Whanin Pharm (2009–2025)
Cash flow-to-debt ratio of Whanin Pharm from 2009 to 2025. Historical debt coverage capacity for Whanin Pharm across 13 annual periods. Check 016580 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Whanin Pharm Cash Flow-to-Debt Ratio by Year (2009–2025)
Whanin Pharm cash flow-to-debt ratio by year from 2009 to 2025. Year-by-year debt coverage analysis for Whanin Pharm. For the full cash flow conversion analysis, see Whanin Pharm operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.16x | ₩9.04 Billion | ₩57.88 Billion | ▼ -63.2% |
| 2024 | 0.42x | ₩20.69 Billion | ₩48.70 Billion | ▼ -21.2% |
| 2023 | 0.54x | ₩23.20 Billion | ₩43.02 Billion | ▲ +13.4% |
| 2022 | 0.48x | ₩16.85 Billion | ₩35.45 Billion | ▼ -51.6% |
| 2021 | 0.98x | ₩35.32 Billion | ₩35.96 Billion | ▲ +42.2% |
| 2020 | 0.69x | ₩22.75 Billion | ₩32.96 Billion | ▼ -15.1% |
| 2019 | 0.81x | ₩24.73 Billion | ₩30.42 Billion | ▲ +30.9% |
| 2018 | 0.62x | ₩17.45 Billion | ₩28.10 Billion | ▼ -16.0% |
| 2017 | 0.74x | ₩23.48 Billion | ₩31.75 Billion | ▼ -13.0% |
| 2016 | 0.85x | ₩19.82 Billion | ₩23.31 Billion | ▼ -23.9% |
| 2012 | 1.12x | ₩21.11 Billion | ₩18.90 Billion | ▲ +20.1% |
| 2011 | 0.93x | ₩15.12 Billion | ₩16.25 Billion | ▼ -47.5% |
| 2009 | 1.77x | ₩18.61 Billion | ₩10.51 Billion | — |